EP Patent

EP1593384A3 — Compositions for treatment of sexual dysfunction

Assigned to Palatin Technologies Inc · Expires 2006-04-26 · 20y expired

What this patent protects

Compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, including a cyclic peptide with a carboxyl terminus -OH group and with the sequence His-Phe-Arg-Trp (SEQ ID NO…

USPTO Abstract

Compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, including a cyclic peptide with a carboxyl terminus -OH group and with the sequence His-Phe-Arg-Trp (SEQ ID NO:1) or His-D-Phe-Arg-Trp. Methods of administration include injection, oral, nasal and mucosal administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP1593384A3
Jurisdiction
EP
Classification
Expires
2006-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Palatin Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.